Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection

Bibliography

• Palella F, Baker R, Moorman A, Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34
   PubMed Web of Science ®Google Scholar
• Das K, Bauman J, Clark A, High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 2008;105:1466-71
   PubMed Web of Science ®Google Scholar
• Das K, Clark A, Lewi P, Roles of conformational and positional adaptability in structure-based design of TMC125–R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550-60
   PubMed Web of Science ®Google Scholar
• Lansdon E, Brendza K, Hung M, Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 2010;53:4295-9
   PubMed Web of Science ®Google Scholar
• Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010;85(1):176-89
   PubMedGoogle Scholar
• De Bethune M, Andries K, Azijn H, TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile [abstract 556]. 12th Conference on Retroviruses and Opportunistic Infections; 22 – 25 February 2005; Boston, MA
   Google Scholar
• Verloes R, Van't Klooster G, Baert L, TMC278 long acting – a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers [abstract TUPE0042]. XVIIth International AIDS Conference; 3 – 8 August 2008; Mexico City, Mexico
   Google Scholar
• Pozniak A, Morales-Ramirez J, Katabira E, Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010;24:55-65
   PubMed Web of Science ®Google Scholar
• Crauwels H, Williams P, Boven K, TMC278 drug-drug interactions: an overview [abstract TPOI-4]. 4th Annual American Conference for the Treatment of HIV (ACTHIV); 7 – 9 April 2011; Denver, CO, USA
   Google Scholar
• Molina JM, Cahn P, Grinsztejn B, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase III randomized double-blind active-controlled trial. Lancet 2011;378:238-46
   PubMed Web of Science ®Google Scholar
• Cohen C, Andrade-Villanueva J, Clotet B, Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase III, randomised, non-inferiority trial. Lancet 2011;378:229-37
   PubMed Web of Science ®Google Scholar
• Hodder S, Arasteh K, De Wet J, Effect of gender and race analyses on week 48 efficacy and safety findings in treatment-naive, HIV-1-infected patients enrolled in ECHO and THRIVE [abstract 1124]. 48th Annual Meeting of the Infectious Diseases Society of America; 21 – 24 October 2010; Vancouver, Canada
   Google Scholar
• Cohen C, Molina JM, Cassetti I, Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults [abstract TULBPE 032]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17 – 20 July 2011; Rome, Italy
   Google Scholar
• Soriano V, Arasteh K, Migrone H, Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011;16(3):339-48
   PubMed Web of Science ®Google Scholar
• Gallego L, Barreiro P, Lopez-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev 2011;13(3):171-9
   PubMed Web of Science ®Google Scholar
• Ford N, Lee J, Andrieux-Meyer I, Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl) 2011;3:35-44
   PubMedGoogle Scholar
• Mills A, Antinori A, Clotet B, Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naive, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks [abstract O-306]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February – 2 March 2011; Boston, MA, USA
   Google Scholar
• Wohl D, Doroana M, Orkin C, Change in Vitamin D levels smaller and risk of development of severe Vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial [abstract 79-LB]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February – 2 March 2011; Boston, MA, USA
   Google Scholar
• Edurant label information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf [Last accessed 12 February 2012]
   Google Scholar
• Edurant EMEA assessment report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002264/WC500118872.pdf [Last accessed 12 February 2012]
   Google Scholar
• Xu H, Oliveira M, Quan Y, Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. J Antimicrob Chemother 2010;65:2291-9
   PubMedGoogle Scholar
• Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009;11:165-73
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27; K138N
   PubMed Web of Science ®Google Scholar
• Rimsky L, Vingerhoets J, Van Eygen V, Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase III ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012;59(1):39-46
   PubMed Web of Science ®Google Scholar
• Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011;85:11309-14
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Anta L, Garcia F, HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. AIDS Rev 2009;11:39-51
   PubMedGoogle Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 20 October 2011]
   Google Scholar